We only use cookies that are necessary for this site to function to provide you with the best experience. The controller of this site may choose to place supplementary cookies to support additional functionality such as support analytics, and has an obligation to disclose these cookies. Learn more in our Cookie Statement.
NEW! Earn 13.25 CEs: SBIA | Generic Drugs Forum 2024: Regulatory Considerations to Enhance Generic Drug Access
U.S. Food and Drug Administration sent this bulletin at 03/27/2024 10:01 AM EDT
The Generic Drugs Forum is an annual, two-day event that offers attendees the opportunity to hear from FDA subject matter experts from every part of the pre-ANDA program and ANDA assessment program. The goal of the forum is to provide practical regulatory information to aid prospective applicants in submitting complete and high-quality applications to maximize the efficiency and utility of each assessment cycle, with the intent to reduce the number of assessment cycles and facilitate timely access to safe, effective, and high-quality generic medicines.
This year’s theme is Regulatory Considerations to Enhance Generic Drug Access, and our agenda will address essential regulatory information on how to engage with the Agency and gain information about ANDA development and ANDA assessment.
This event has been approved for a maximum of 13.25 contact hours of continuing education for physicians, pharmacists, and nurses. Please see detailed announcement for more information.
Participants can also obtain a certificate of attendance which can be used in support of CEs for the following professional organizations: RAPS, SOCRA, SQA, and ACRP. Certificates are only available during the two weeks post-event. For more information, see details on our webpage.
*Registration and real-time attendance via Adobe Connect is required for CE eligibility and the certificate of attendance.
The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research provides guidance, education and updates for regulated industry.